CA3149868A1 - Antibacterial compounds - Google Patents
Antibacterial compounds Download PDFInfo
- Publication number
- CA3149868A1 CA3149868A1 CA3149868A CA3149868A CA3149868A1 CA 3149868 A1 CA3149868 A1 CA 3149868A1 CA 3149868 A CA3149868 A CA 3149868A CA 3149868 A CA3149868 A CA 3149868A CA 3149868 A1 CA3149868 A1 CA 3149868A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mmol
- alkyl
- dcm
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197183.7 | 2019-09-13 | ||
| EP19197183 | 2019-09-13 | ||
| PCT/EP2020/075458 WO2021048342A1 (en) | 2019-09-13 | 2020-09-11 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3149868A1 true CA3149868A1 (en) | 2021-03-18 |
Family
ID=67956507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3149868A Pending CA3149868A1 (en) | 2019-09-13 | 2020-09-11 | Antibacterial compounds |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220340564A1 (https=) |
| EP (1) | EP4028399B1 (https=) |
| JP (1) | JP7680433B2 (https=) |
| CN (1) | CN114423758B (https=) |
| AU (1) | AU2020346370B2 (https=) |
| BR (1) | BR112022003799A2 (https=) |
| CA (1) | CA3149868A1 (https=) |
| ES (1) | ES2978573T3 (https=) |
| MX (1) | MX2022003037A (https=) |
| WO (1) | WO2021048342A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348510B (zh) | 2015-09-17 | 2022-01-04 | 圣母大学 | 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物 |
| EP4308239A1 (en) * | 2021-03-16 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| IL312366A (en) | 2021-10-28 | 2024-06-01 | Janssen Sciences Ireland Unlimited Co | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1527050T3 (da) | 2002-07-25 | 2010-07-19 | Janssen Pharmaceutica Nv | Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer |
| CA2793086C (en) | 2010-03-18 | 2018-08-21 | Institut Pasteur Korea | Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| EP2751104B1 (en) | 2011-09-01 | 2019-09-25 | Novartis AG | Compounds and compositions as c-kit kinase inhibitors |
| US9605002B2 (en) * | 2012-07-18 | 2017-03-28 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
| DK3027615T3 (da) | 2013-08-02 | 2021-10-25 | Pasteur Institut Korea | Antiinfektionsforbindelser |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| BR112017028318B1 (pt) | 2015-07-02 | 2024-02-20 | Janssen Sciences Ireland Uc | Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação |
| CN108348510B (zh) * | 2015-09-17 | 2022-01-04 | 圣母大学 | 针对分枝杆菌感染有用的含有苄胺的杂环化合物以及组合物 |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| MX2018015657A (es) * | 2016-06-16 | 2019-03-14 | Janssen Sciences Ireland Unlimited Co | Compuestos heterociclico como antibacterianos. |
| WO2018084809A1 (en) * | 2016-11-02 | 2018-05-11 | Nanyang Technological University | Methods for the treatment or prevention of mycobacterial infections |
-
2020
- 2020-09-11 WO PCT/EP2020/075458 patent/WO2021048342A1/en not_active Ceased
- 2020-09-11 US US17/639,963 patent/US20220340564A1/en active Pending
- 2020-09-11 CN CN202080064727.XA patent/CN114423758B/zh active Active
- 2020-09-11 BR BR112022003799A patent/BR112022003799A2/pt unknown
- 2020-09-11 AU AU2020346370A patent/AU2020346370B2/en active Active
- 2020-09-11 CA CA3149868A patent/CA3149868A1/en active Pending
- 2020-09-11 EP EP20776062.0A patent/EP4028399B1/en active Active
- 2020-09-11 JP JP2022516117A patent/JP7680433B2/ja active Active
- 2020-09-11 ES ES20776062T patent/ES2978573T3/es active Active
- 2020-09-11 MX MX2022003037A patent/MX2022003037A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114423758A (zh) | 2022-04-29 |
| KR20220062564A (ko) | 2022-05-17 |
| MX2022003037A (es) | 2022-04-07 |
| EP4028399C0 (en) | 2024-02-14 |
| WO2021048342A1 (en) | 2021-03-18 |
| EP4028399A1 (en) | 2022-07-20 |
| US20220340564A1 (en) | 2022-10-27 |
| CN114423758B (zh) | 2025-05-27 |
| JP7680433B2 (ja) | 2025-05-20 |
| AU2020346370B2 (en) | 2026-02-12 |
| JP2022548247A (ja) | 2022-11-17 |
| ES2978573T3 (es) | 2024-09-16 |
| BR112022003799A2 (pt) | 2022-05-24 |
| EP4028399B1 (en) | 2024-02-14 |
| AU2020346370A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3149868A1 (en) | Antibacterial compounds | |
| US11179396B2 (en) | Heterocyclic compounds as antibacterials | |
| AU2016287478B2 (en) | Antibacterial compounds | |
| AU2017286370B2 (en) | Heterocyclic compounds as antibacte rials | |
| CA3212074A1 (en) | Antibacterial compounds | |
| US20240199651A1 (en) | Antibacterial compounds | |
| CA3211532A1 (en) | Antibacterial compounds | |
| KR102955654B1 (ko) | 항균 화합물 | |
| HK40080567B (en) | Antibacterial compounds | |
| HK40080567A (en) | Antibacterial compounds | |
| WO2022214520A1 (en) | Antibacterial compounds | |
| OA19079A (en) | Antibacterial compounds. | |
| OA19129A (en) | Heterocyclic compounds as antibacterials. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220919 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250609 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250729 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251007 |